{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:49:51Z","timestamp":1791625791125,"version":"4.3.4"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health"},{"name":"Cancer Center Support Grant awarded to the UC San Diego Moores Cancer Center","award":["2P30CA023100-38"],"award-info":[{"award-number":["2P30CA023100-38"]}],"id":[{"id":"https:\/\/ror.org\/01qkmtm61","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite advances in metastatic androgen pathway modulation-sensitive prostate cancer (mAPMS) treatment, outcomes remain heterogeneous. Achieving a post-treatment undetectable prostate-specific antigen (PSA) is a strong prognostic marker. We aimed to identify genomic and transcriptomic determinants of PSA response in a real-world clinical-genomic cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients with mAPMS who underwent DNA (Tempus xT) and, in a subset, RNA (Tempus xR) sequencing were identified from the Tempus Lens database. Inclusion required stage IV disease within 90\u2009days of sample collection and obtained within 12\u2009months before or 3\u2009months after treatment initiation. Patients with PSA at 6\u2009months (n\u2009=\u2009525) were classified as PSA-Low (&amp;lt;0.1\u2009ng\/mL, n\u2009=\u2009240) or PSA-High (\u22650.1\u2009ng\/mL, n\u2009=\u2009285). Overall survival (OS) was assessed by 6-month landmark analysis with delayed-entry adjustment. Logistic and Cox models were adjusted for clinical variables. Sensitivity analyses used a relative definition of &amp;gt;95% PSA decline from baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline PSA was lower in PSA-Low versus PSA-High patients (24 vs 36\u2009ng\/mL, P\u2009=\u2009.01). SPOP (17% vs 11%) and ZFHX3 (2.5% vs 6%) alterations differed between groups, but neither persisted after adjustment. Using the relative definition, ZMYM3 and JAK1 alterations were independently associated with failure to achieve a deep PSA response. Expression of PSMA, TROP2, B7-H3, and STEAP1 did not differ between groups. PSA-Low status was independently associated with improved OS, as was deep relative response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Deep PSA response at 6\u2009months correlates with improved OS in mAPMS. Integrating molecular markers with PSA response may inform treatment intensification or de-escalation strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag368","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:25:05Z","timestamp":1789651505000},"source":"Crossref","is-referenced-by-count":0,"title":["Genomic and transcriptomic correlates of deep prostate\u2013specific antigen response in patients with metastatic androgen pathway modulation\u2013sensitive prostate cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-7963","authenticated-orcid":false,"given":"Rana R","family":"McKay","sequence":"first","affiliation":[{"name":"Moores Cancer Center, University of California San Diego , La Jolla, CA 92093,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin , Milwaukee, WI 53226,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8845-5390","authenticated-orcid":false,"given":"Binyam","family":"Yilma","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc , Chicago, IL 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnati","family":"Jariwala","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc , Chicago, IL 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arya","family":"Ashok","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc , Chicago, IL 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stamatina","family":"Fragkogianni","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc , Chicago, IL 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Mercer","sequence":"additional","affiliation":[{"name":"Tempus AI, Inc , Chicago, IL 60654,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Utah , Salt Lake City, UT 84112,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0031-9655","authenticated-orcid":false,"given":"Emmanuel S","family":"Antonarakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Masonic Cancer Center, University of Minnesota , Minneapolis, MN 55455,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"2026101005120048700_oyag368-B1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026101005120048700_oyag368-B2","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026101005120048700_oyag368-B3","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026101005120048700_oyag368-B4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026101005120048700_oyag368-B5","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"2026101005120048700_oyag368-B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101005120048700_oyag368-B7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026101005120048700_oyag368-B8","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1200\/JCO.2025.43.16_suppl.5090","article-title":"8-Year outcomes of enzalutamide (ENZA) versus a non-steroidal anti-androgen (NSAA) for metastatic, hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304)","volume":"43","author":"Zhang","year":"2025","journal-title":"JCO"},{"key":"2026101005120048700_oyag368-B9","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.annonc.2025.08.004","article-title":"Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"36","author":"Tripathi","year":"2025","journal-title":"Ann Oncol"},{"key":"2026101005120048700_oyag368-B10","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026101005120048700_oyag368-B11","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.eururo.2024.03.036","article-title":"Deep and durable prostate-specific antigen response to darolutamide with androgen deprivation therapy and docetaxel, and association with clinical outcomes for patients with high- or low-volume metastatic hormone-sensitive prostate cancer: analyses of the randomized phase 3 ARASENS study","volume":"86","author":"Saad","year":"2024","journal-title":"Eur Urol"},{"key":"2026101005120048700_oyag368-B12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41467-025-67298-z","article-title":"Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer","volume":"17","author":"Roy","year":"2025","journal-title":"Nat Commun"},{"key":"2026101005120048700_oyag368-B13","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.euo.2024.03.001","article-title":"Three- and seven-month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone-sensitive prostate cancer: Results from SWOG S1216, a phase 3 randomized trial of androgen deprivation plus orteronel or bicalutamide","volume":"7","author":"Parikh","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"2026101005120048700_oyag368-B14","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2025.43.16_suppl.5002","article-title":"Prognostic significance of PSA&gt; 0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry","volume":"43","author":"Ong","year":"2025","journal-title":"JCO"},{"key":"2026101005120048700_oyag368-B15","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.eururo.2019.11.021","article-title":"Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study","volume":"77","author":"Matsubara","year":"2020","journal-title":"Eur Urol"},{"key":"2026101005120048700_oyag368-B16","doi-asserted-by":"publisher","first-page":"S1162","DOI":"10.1016\/j.annonc.2022.07.1493","article-title":"1361MO 8-month PSA strongly predicts outcomes of men with metastatic castration-sensitive prostate cancer in the PEACE-1 phase III trial","volume":"33","author":"Gravis Mescam","year":"2022","journal-title":"Ann Oncol"},{"key":"2026101005120048700_oyag368-B17","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"2026101005120048700_oyag368-B18","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026101005120048700_oyag368-B19","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026101005120048700_oyag368-B20","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","author":"Cancer Genome Atlas Research Network","year":"2015","journal-title":"Cell"},{"key":"2026101005120048700_oyag368-B21","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","article-title":"Genomic correlates of clinical outcome in advanced prostate cancer","volume":"116","author":"Abida","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026101005120048700_oyag368-B22","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1158\/1078-0432.CCR-22-2228","article-title":"SPOP mutations as a predictive biomarker for androgen receptor axis-targeted therapy in de novo metastatic castration-sensitive prostate cancer","volume":"28","author":"Swami","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026101005120048700_oyag368-B23","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.eururo.2020.06.033","article-title":"Reply to Salma Kaochar, Nicholas Mitsiades\u2019 Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig Association of SPOP mutations with outcomes in men with de novo metastatic castration-sensitive prostate cancer. Eur urol 2020, 78:652-6. Can mutant SPOP become an actionable biomarker for precision oncology management of prostate cancer?: SPOP as a potential treatment selection marker in prostate cancer","volume":"78","author":"Swami","year":"2020","journal-title":"Eur Urol"},{"key":"2026101005120048700_oyag368-B24","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","article-title":"SPOP-Mutated\/CHD1-deleted lethal prostate cancer and abiraterone sensitivity","volume":"24","author":"Boysen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026101005120048700_oyag368-B25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/1078-0432.CCR-24-3471","article-title":"Structurally oriented classification of FOXA1 alterations identifies prostate cancers with opposing clinical outcomes and distinct molecular and immunologic subtypes","volume":"31","author":"Hwang","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026101005120048700_oyag368-B26","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1038\/s41467-022-31769-4","article-title":"Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer","volume":"13","author":"Lau","year":"2022","journal-title":"Nat Commun"},{"key":"2026101005120048700_oyag368-B27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00262-022-03252-y","article-title":"Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer","volume":"72","author":"Gao","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026101005120048700_oyag368-B28","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026101005120048700_oyag368-B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"2026101005120048700_oyag368-B30","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41389-019-0138-y","article-title":"ZFHX3 is indispensable for ERbeta to inhibit cell proliferation via MYC downregulation in prostate cancer cells","volume":"8","author":"Hu","year":"2019","journal-title":"Oncogenesis"},{"key":"2026101005120048700_oyag368-B31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41420-024-02060-w","article-title":"ZFHX3 acts as a tumor suppressor in prostate cancer by targeting FTO-mediated m(6)A demethylation","volume":"10","author":"Hu","year":"2024","journal-title":"Cell Death Discov"},{"key":"2026101005120048700_oyag368-B32","doi-asserted-by":"publisher","first-page":"20931","DOI":"10.1038\/s41598-025-05659-w","article-title":"ZFHX3 is integral to androgen\/AR signaling involving protein association with AR in prostate cancer cells","volume":"15","author":"Fu","year":"2025","journal-title":"Sci Rep"},{"key":"2026101005120048700_oyag368-B33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/bjc.2012.549","article-title":"Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer","volume":"108","author":"S\u00f8rensen","year":"2013","journal-title":"Br J Cancer"},{"key":"2026101005120048700_oyag368-B34","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.euros.2025.12.011","article-title":"Downregulation of ANPEP is associated with aggressive prostate cancer and poor disease-specific outcomes","volume":"83","author":"Putney","year":"2026","journal-title":"Eur Urol Open Sci"},{"key":"2026101005120048700_oyag368-B35","doi-asserted-by":"publisher","first-page":"e13363","DOI":"10.1371\/journal.pone.0013363","article-title":"The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine","volume":"5","author":"Whitaker","year":"2010","journal-title":"PLoS One"},{"key":"2026101005120048700_oyag368-B36","doi-asserted-by":"publisher","first-page":"152464","DOI":"10.1016\/j.prp.2019.152464","article-title":"HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer","volume":"215","author":"Wan","year":"2019","journal-title":"Pathol Res Pract"},{"key":"2026101005120048700_oyag368-B37","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.prostaglandins.2006.05.015","article-title":"DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation","volume":"82","author":"Kelavkar","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2026101005120048700_oyag368-B38","doi-asserted-by":"publisher","first-page":"1042420","DOI":"10.3389\/fphar.2022.1042420","article-title":"Arachidonate 15-lipoxygenase type B: regulation, function, and its role in pathophysiology","volume":"13","author":"Benatzy","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026101005120048700_oyag368-B39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1210\/me.2005-0287","article-title":"Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha, 17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease","volume":"20","author":"Bauman","year":"2006","journal-title":"Mol Endocrinol"},{"key":"2026101005120048700_oyag368-B40","doi-asserted-by":"publisher","first-page":"8404","DOI":"10.1038\/s41467-024-52659-x","article-title":"SURF2 is a MDM2 antagonist in triggering the nucleolar stress response","volume":"15","author":"Tagn\u00e8res","year":"2024","journal-title":"Nat Commun"},{"key":"2026101005120048700_oyag368-B41","doi-asserted-by":"publisher","first-page":"616173","DOI":"10.3389\/fonc.2020.616173","article-title":"TBX1 functions as a tumor activator in prostate cancer by promoting ribosome RNA gene transcription","volume":"10","author":"Cui","year":"2020","journal-title":"Front Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag368\/71189020\/oyag368.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag368\/71189020\/oyag368.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag368\/71189020\/oyag368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T09:12:09Z","timestamp":1791623529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag368\/8812274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag368","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,9,17]]},"article-number":"oyag368"}}